File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3748/wjg.v19.i47.8887
- Scopus: eid_2-s2.0-84890904585
- PMID: 24379612
- WOS: WOS:000329129400010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
Title | Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection |
---|---|
Authors | |
Keywords | Hepatitis B virus Hepatitis C virus Hepato-cellular carcinoma Prevention Vaccination |
Issue Date | 2013 |
Publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm |
Citation | World Journal of Gastroenterology, 2013, v. 19 n. 47, p. 8887-8894 How to Cite? |
Abstract | Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer. |
Persistent Identifier | http://hdl.handle.net/10722/193875 |
ISSN | 2023 Impact Factor: 4.3 2023 SCImago Journal Rankings: 1.063 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lu, T | en_US |
dc.contributor.author | Seto, WKW | en_US |
dc.contributor.author | Zhu, RX | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, RMF | en_US |
dc.date.accessioned | 2014-01-28T06:30:43Z | - |
dc.date.available | 2014-01-28T06:30:43Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | World Journal of Gastroenterology, 2013, v. 19 n. 47, p. 8887-8894 | en_US |
dc.identifier.issn | 1007-9327 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/193875 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer. | en_US |
dc.language | eng | en_US |
dc.publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm | - |
dc.relation.ispartof | World Journal of Gastroenterology | en_US |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Hepatitis B virus | - |
dc.subject | Hepatitis C virus | - |
dc.subject | Hepato-cellular carcinoma | - |
dc.subject | Prevention | - |
dc.subject | Vaccination | - |
dc.title | Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection | en_US |
dc.type | Article | en_US |
dc.identifier.email | Seto, WKW: wkseto2@hku.hk | en_US |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | en_US |
dc.identifier.authority | Seto, WKW=rp01659 | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3748/wjg.v19.i47.8887 | en_US |
dc.identifier.pmid | 24379612 | - |
dc.identifier.pmcid | PMC3870540 | - |
dc.identifier.scopus | eid_2-s2.0-84890904585 | - |
dc.identifier.hkuros | 227481 | en_US |
dc.identifier.volume | 19 | en_US |
dc.identifier.issue | 47 | en_US |
dc.identifier.spage | 8887 | en_US |
dc.identifier.epage | 8894 | en_US |
dc.identifier.isi | WOS:000329129400010 | - |
dc.publisher.place | China | - |
dc.identifier.issnl | 1007-9327 | - |